IBM Research Update: What the Abcuro Clinical Trial Reveals hosted by TMA WomenwithIBM Affinity Group
Join us, TMA’s WomenWithIBM Affinity Group, for a timely conversation on Abcuro’s newly-released topline results from the MUSCLE study of ulviprubart (ABC008) for Inclusion Body Myositis. OPEN TO ALL.
Dr. Namita Goyal, Principal Investigator, will explain what the findings show and what’s ahead after the data is presented at the 6th Global Conference on Myositis in Lisbon.
📅 Friday, April 3, 2026 ⏰ 12:00–1:30 PM ET
💻 Zoom 🔗 Registration Link: Register here.
A meaningful moment for everyone in the Myositis community to hear directly from a leading expert.
Created in 2020, the mission of TMA WomenwithIBM Affinity Group is to improve the lives of women with inclusion body myositis through virtual connections and support that transcends geography. Meets on the third Tuesday of most months at 12 PM ET | 11 AM CT | 10 AM MT | 9 AM PT.
